Clinical and Economic Impact of Implementing OVIVA Criteria on Patients With Bone and Joint Infections in Outpatient Parenteral Antimicrobial Therapy.
- Resource Type
- Article
- Authors
- Marks, Michael; Bell, Lucy C K; Jones, Imogen; Rampling, Tommy; Kranzer, Katharina; Morris-Jones, Stephen; Logan, Sarah; Pollara, Gabriele
- Source
- Clinical Infectious Diseases. 7/1/2020, Vol. 71 Issue 1, p207-210. 4p.
- Subject
- *ANTIBIOTICS
*BONE diseases
*INFECTIOUS arthritis
*INTRAVENOUS therapy
*JOINT diseases
*ORAL drug administration
*PARENTERAL infusions
- Language
- ISSN
- 1058-4838
The OVIVA study demonstrated noninferiority for managing bone and joint infections (BJIs) with oral antibiotics. We report that 79.7% of OPAT patients being treated for BJIs at our center would be eligible for oral antibiotics, saving a median (IQR) 19.5 IV-antibiotic days (8.5–37) and GBP 1234 (569–2594) per patient. [ABSTRACT FROM AUTHOR]